ProKidney Corp
PROK
Company Profile
Business description
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Contact
2000 Frontis Plaza Boulevard
Suite 250
Winston-SalemNC27103
USAT: +1 336 999-7019
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
231
Stocks News & Analysis
stocks
Cheap ASX share may have more room to run
Shares are cheap despite rebounding share price, yet risks remain.
stocks
ASX listed media giant drives strong earnings growth
Digital growth drives earnings beat for media share.
stocks
ASX real estate platform outperforms yet questions remain
Valuation remains a key concern despite strong August reporting.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,424.10 | 13.30 | -0.14% |
| CAC 40 | 8,715.32 | 0.39 | 0.00% |
| DAX 40 | 26,357.57 | 38.12 | 0.14% |
| Dow JONES (US) | 54,036.93 | 151.83 | 0.28% |
| FTSE 100 | 10,886.68 | 14.41 | -0.13% |
| HKSE | 25,902.16 | 234.13 | 0.91% |
| NASDAQ | 26,690.62 | 342.26 | 1.30% |
| Nikkei 225 | 66,970.22 | 1,363.51 | 2.08% |
| NZX 50 Index | 13,888.24 | 64.11 | 0.46% |
| S&P 500 | 7,757.64 | 47.68 | 0.62% |
| S&P/ASX 200 | 9,232.60 | 17.00 | -0.18% |
| SSE Composite Index | 3,966.59 | 26.56 | 0.67% |